Estuary Biotherapeutics has launched with $103 million in committed financing to develop kidney-targeted gene therapies for autosomal dominant polycystic kidney disease. Its two lead programmes target PKD2 and PKD1 mutations, building on mouse research suggesting that restoring polycystin activity can reverse some features of established kidney disease.
The all-stock transaction values Ambros Therapeutics at $500 million and pairs its pivotal neridronate programme with a $150 million financing designed to fund development through Phase 3 data and an FDA filing.
Werewolf and Ambros secure $150m to fund neridronate through its pivotal CRPS-1 Phase 3 readout and planned FDA filing. See what is at stake.
Biohaven and Yale won a $4 million MODA trade secret verdict, strengthening the platform narrative as BHV-1300 enters Phase 3.
Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive
Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.